anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for treatment of highly active relapsing multiple sclerosis (MS) but requires vigilant post-treatment monitoring due to associated risks. The prescription of subsequent therapies following Alemtuzumab, as mandated by label guidance for a treatment-free period of at least 5 years, presents a complex challenge, particularly if there is concurrent conversion to secondary progressive disease course. We described a case-series of five patients starting therapy with Siponimod and followed up for 12 months period converted to secondary progressive MS previously exposed to Alemtuzumab. All patients received Siponimod 2 mg. Clinical evaluation measured with Expanded Disability Status Scale and cognitive evaluation measured with Brief International Cognitive Assessment for Multiple Sclerosis were stable after 12 months on therapy. No severe lymphopenia was recorded, nor serious adverse events. In conclusion, the long-term management of patients treated with Alemtuzumab transitioning to secondary progressive MS requires a proactive and multidisciplinary approach. By addressing the challenges associated with treatment limitations and short-term monitoring recommendations while considering alternative therapeutic options like Siponimod, clinicians can optimize outcomes and ensure continuity of care for individuals with MS.
The invention discloses a night shade all-grass and / or fruit extractive, the drug preparation and the preparation method. In the night shade all-grass and / or fruit extractive, the content of the night shade all alkali occupies more than 50 percent. The drug preparation of the night shade total alkali extractive contains 1-99 percent of night shade total alkali extractive containing 50-99 percent of night shade total alkali and 99-1 percent medical excipient (containing other drugs for compatibility). The pharmacodynamic experimental result shows that Solanum nigrum total Alkaloids has strong restraining action to various tumor cells, has strong tumor repressing function to Hep,S180 implanted solid tumor, has evident antitumor synergia action to tumor radiation treatment and chemo-treatment on animal implanted; therefore the extractive is proved to have good tumor depressing function. The pharmacological and the toxicological experiments testify the safety of the invention in use. The invention has the advantages of advanced process, good tumor depressing function and relative low cost.
The NMDP Cord Blood registry is organized as a network of member cord blood banks and transplant centers whose interactions are managed by the NMDP's Center for Cord Blood. Banks agree to comply with uniform collection, screening, testing and storage requirements. Upon approval of membership, cord blood banks submit detailed information on each stored CBU for registration into a proprietary computer system. A transplant center, working on behalf of potential recipients, submits search requests to the NMDP and receives electronic reports detailing potentially suitable CBUs. From these reports, the transplant center selects a CBU(s) for further testing, which includes at a minimum confirmation of the CBUs Human Leukocyte Antigen (HLA) typing data. Upon final selection of the desired CBU for transplantation, arrangements are made for timely shipment of the unit to the transplant center. Following transplantation, recipient outcome data are submitted by the transplant center for addition to the study database.
PURPOSE: The dosimetry of scalp dose was prospectively studied and correlated with alopecia following conventional cranial irradiation in primary brain tumors patients.
MATERIALS AND METHODS: Patients with primary brain tumors who required conventional radiotherapy were enrolled. A hairline marker was applied to the patient's scalp to identify the entire scalp region. The maximal dose to 2% volume of interest (D2) for the entire scalp region were obtained. The radiation dosages at the localized hair-loss areas were evaluated during the final week of RT (transient alopecia) and six months after completing RT (permanent alopecia). Kruskal-Wallis tests were used to compare the dosimetric parameter values with statistical significance set as p < 0.05.
RESULTS: Forty-eight patients were included in the analysis. The prescribed radiation doses ranged from 50.4 to 60.0 Gy. Thirty-two patients experienced alopecia (27 transient and 5 permanent). The median D2 values adjusted for the entire scalp were higher in the alopecia group (38.40 Gy for transient alopecia and 47.84 Gy for permanent alopecia vs 11.90 Gy for no alopecia, p < 0.001). The D2 value was determined as a predictive parameter for alopecia. The threshold values for transient and permanent alopecia over the entire scalp were 22.15 Gy and 36.81 Gy, respectively. At the localized hair-loss areas, the D2 values for transient and permanent alopecia were higher at 44.82 Gy and 50.00 Gy, respectively. The radiation intensity at the localized hair-loss areas was also related to the severity of alopecia, with D2 values of 35.14 Gy and 46.39 Gy for clinically assigned grade 1 and grade 2 transient alopecia, respectively, with the D2 value being even higher for permanent alopecia.
CONCLUSIONS: The D2 parameter value could be used to predict the type and severity of alopecia.
Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
INTRODUCTION: Vascular dementia (VaD), a neurocognitive impairment directly related to vascular injury, is the second most common cause of age-related dementia. Although numerous studies have investigated candidate genetic polymorphisms associated with VaD in Asia, the genetics of VaD remains unclear.
METHODS: This review provides an updated meta-analysis of genetic polymorphisms associated with VaD in Asians, using the PRISMA guidelines. Published literature up to May 2021 was extracted from the PubMed, Scopus, Ovid, and EBSCOhost databases. Meta-analysis was conducted using the Open Meta analyst, Review Manager, and MedCalc® Statistical Software. Trial sequential analysis (TSA) was performed using TSA viewer software.
RESULTS: A total of 46 eligible studies, comprising 23 genes and 35 single nucleotide polymorphisms, were retrieved. The meta-analysis was conducted on the following genetic polymorphisms, APOE ε2/3/4, MTHFR rs1801131, ACE rs4340 (I/D) gene polymorphism, and a PSEN1 intron 8 variant. The pooled odds ratio (ORs) revealed a significant increase in the risk of VaD in the apolipoprotein E (APOE) ε4 allelic model (OR, 1.79, p < 0.001), and the methylenetetrahydrofolate reductase (MTHFR) rs1801133 polymorphism T allele in the allelic model (OR, 1.23, p = 0.013).
CONCLUSION: Our findings provide evidence that genetic polymorphisms of the APOE ε4 allele and MTHFR rs1801133 T allele increase the risk of developing VaD in Asians. However, future large-scale investigations examining particularly on South-Eastern and West-Asian populations are highly recommended.
A method for predicting a depressive state using a wearable device. Each data type of biological data for several days from plurality of subjects is converted into data in predetermined time unit (S 201 ). Next, quantiles of the distribution of obtained sample data are determined for each subject and each data type (S 202 ). The standard deviation of distribution of the obtained sample data is calculated for each subject and each data type (S 203 ). The Pearson correlation coefficient is calculated for each combination of data types for each subject (S 204 ). Next, a prediction model for the classification problem of whether subject is in a depressive state is trained by machine leaning (S 206 ), wherein quantiles, standard deviations, and Pearson correlation coefficients extracted from the biological data are features used for an input vector, and an evaluation of existence or non-existence of a depressive state by an expert is a label used as teacher data.
INTRODUCTION: Laparoscopic sacrocolpopexy (LSCP) is currently the gold standard surgical technique for treating pelvic prolapse. This study aimed to evaluate the feasibility of laparoscopic sacrocolpopexy in ambulatory care.
PATIENTS AND METHODS: This prospective study was conducted to evaluate the feasibility of LSCP in women who visited the outpatient department of obstetrics and gynecology at the University Hospital of Strasbourg between July 2018 and December 2021. All women with indications for laparoscopic sacrocolpopexy for prolapse treatment who were willing to be treated as outpatients were included. The main criterion of the study was to evaluate the rate of re-hospitalization between discharge from the outpatient department after LSCP and postoperative follow-up consultations.
RESULTS: Among the whole population (57/200, 28.5 %) included, 4 (7 %) were hospitalized. The quality of life was not altered with a preserved EuroQol (EQ-5D) quality of life score with a mean score of 73±18.4 standard deviation (SD) 95 % confidence interval (CI) (67.9; 78.1) on postoperative day 3 (D3) and 91.2 ± 16.3 SD 95 % CI (86.2-96) on D30. On D1, D2, D3, and D7, the anxiety rate evaluated by State-Trait Anxiety Inventory score (STAI Y-A) remained low, with mean scores of 24.8 ± 9.6 SD 95 % [23.4-26.5] on D30. All patients were satisfied or very satisfied with the procedure and outpatient management, with an average score of 9.6/10 (range: 8-10).
CONCLUSION: This prospective, monocentric study evaluating the feasibility of outpatient LSCP reported demonstrated low rates of complications and re-hospitalization after outpatient management. Furthermore, the patients' quality of life was not altered, and they patients were satisfied with this type of management.
OBJECTIVES: The progression of knee osteoarthritis (OA) can be defined as either radiographic progression or pain progression. This study aimed to construct models to predict radiographic progression and pain progression in patients with knee OA.
METHODS: We retrieved data from the FNIH OA Biomarkers Consortium project, a nested case-control study. A total of 600 subjects with mild to moderate OA (Kellgren-Lawrence grade of 1, 2, or 3) in one target knee were enrolled. The patients were classified as radiographic progressors (n = 297), non-radiographic progressors (n = 303), pain progressors (n = 297), or non-pain progressors (n = 303) according to the change in the minimum joint space width of the medial compartment and the WOMAC pain score during the follow-up period of 24-48 months. Initially, 376 variables concerning demographics, clinical questionnaires, imaging measurements, and biochemical markers were included. We developed predictive models based on multivariate logistic regression analysis and visualized the models with nomograms. We also tested whether adding changes in predictors from baseline to 24 months would improve the predictive efficacy of the models.
RESULTS: The predictive models of radiographic progression and pain progression consisted of 8 and 10 variables, respectively, with area under curve (AUC) values of 0.77 and 0.76, respectively. Incorporating the change in the WOMAC pain score from baseline to 24 months into the pain progression predictive model significantly improved the predictive effectiveness (AUC = 0.86).
CONCLUSIONS: We identified risk factors for imaging progression and pain progression in patients with knee OA over a 2- to 4-year period, and provided effective predictive models, which could help identify patients at high risk of progression.
The same method Lifestyle intervention "SOFT" is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy "SOFT" as described by Nowicka \& Flodmark (1-3).
A computer may receive health related data from a plurality of data sources. Upon receiving the health related data, the computer may standardize the health related data based on a reference database. Further, based on a person-centric data framework, the computer may categorize the health related data into historical health related data and current health related data. Then, the computer may calculate a risk score based on the historical health related data and the current health related data. Once the risk score is calculated, the computer may determine a cost associated with a risk represented by the risk score. Further, the computer may generate a overall health score based on the risk score and the determined cost, which may then be transmitted for presentation to authorized end users.
PURPOSE:To obtain a new compound useful as an antimicrobial agent, showing strongly inhibitory effects on multiplication of growth of microorganisms. CONSTITUTION:Antimicrobial substance BE-24566B of the formula or its salt. The compound is obtained by inoculating Streptomyces sp. A24566 strain (FERM P-12,080) into a nutrient source, culturing under an aerobic condition, separating and purifying by extraction with a solvent, etc. Properties of BE-24566B. Light yellow amorphous solid or crystal. Molecular formula: C27H24O7. Elemental analysis value; C 70.36%, H 5.28% (measured value). Melting point: browning approximately at 160-170 deg.C. Solubility: soluble in methanol and dimethyl sulfoxide, slightly soluble in water. Weakly acidic substance. Color reaction: positive in potassium permanganate reaction and sulfuric acid reaction. Showing strongly antimicrobial effects on Gram-positive bacteria including methicillia resistant staphylococcus aureus, useful for treating infectious diseases.
Repurposing regulatory agency-approved molecules, with proven safety in humans, is an attractive option for developing new treatments for disease. We identified and assessed the efficacy of 3 drugs predicted by an in silico screen as having the potential to treat l-DOPA-induced dyskinesia (LID) in Parkinson's disease. We analysed ∼1.3 million Medline abstracts using natural language processing and ranked 3539 existing drugs based on predicted ability to reduce LID. 3 drugs from the top 5% of the 3539 candidates; lorcaserin, acamprosate and ganaxolone, were prioritized for preclinical testing based on i) having a novel mechanism of action, ii) having not been previously validated for the treatment of LID, iii) being blood-brain-barrier penetrant and orally bioavailable and iv) being clinical trial ready. We assessed the efficacy of acamprosate, ganaxolone and lorcaserin in a rodent model of l-DOPA-induced hyperactivity, with lorcaserin affording a 58% reduction in rotational asymmetry (P < 0.05) compared to vehicle. Acamprosate and ganaxolone failed to demonstrate efficacy. Lorcaserin, a 5HT2C agonist, was then further tested in MPTP lesioned dyskinetic macaques where it afforded an 82% reduction in LID (P < 0.05), unfortunately accompanied by a significant increase in parkinsonian disability. In conclusion, although our data do not support the repurposing of lorcaserin, acamprosate or ganaxolone per se for LID, we demonstrate value of an in silico approach to identify candidate molecules which, in combination with an in vivo screen, can facilitate clinical development decisions. The present study adds to a growing literature in support of this paradigm shifting approach in the repurposing pipeline.
Group B will serve as the control group in this study. Participants in this group will receive instructions on how to complete the assignment using traditional online tools available on the internet, without the use of artificial intelligence. They will have a timeframe of six days to complete the assignment using these conventional tools. Similar to participants in Arm 1, they will also be required to fill out a survey on technology usability, providing feedback on their experience with the online tools.
The invention relates to ointment for treating scalding. The ointment comprises, by weight, 3 parts to 8 parts of sesame oil, 2 parts to 7 parts of liquorice, 1 part to 5 parts of rehmannia glutinosa, 6 parts to 9 parts of beeswax, 0.4 part to 0.8 part of scutellaria baicalensis and 0.5 part to 1 part of garden burnet. The ointment for treating scalding has the advantages that ingredients interact, so that scalding can be effectively treated without scars. The ingredients are synergistic, so that the detumescence effect, the inflammation diminishing effect and the analgesic effect can be achieved on the scalded portion, and scalding can be fundamentally treated. The ointment for treating scalding can permeate into the innermost portion of the scalded portion to repair cells of the innermost portion of the scalded portion, scalding is fundamentally cured, complications can be avoided, and sequelae can be avoided. In addition, after scalding is cured through the ointment for treating scalding, the scars are hardly left. Due to the sesame oil, moistening of the skin of the scalded portion can be guaranteed, dividing of the cells is promoted, and therefore the treatment effect is better. The ointment for treating scalding is convenient to use, high in effect taking speed and short in treatment course.
Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and were individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
Checkpoint inhibitor induced pneumonia (CIP) is clinically characterized as dyspnea, cough, and tachypnea. Hypoxia is caused by lymphocyte-predominant alveolitis, resulting in gross vitreous shadows and consolidation observed by CT scans. Histological findings included lymphocyte infiltration, granuloma formation and eosinophilic accumulation. In the management of CIP, systemic administration of steroids such as methylprednisolone is the standard therapy. Furthermore, CIP in most cases leads to interruption of checkpoint inhibition therapy and steroids limit the therapeutic effect of checkpoint inhibitors, leading to potential malignant disease progression. Thus, there is a need for additional treatment options in CIP that ideally eliminate alveolar inflammation induced by checkpoint inhibitors without affecting the systemic effects on the immune system. The focus of the present invention is to provide a solution to this problem by local administration of VIP (vasoactive intestinal peptide, a 28 amino acid peptide). Drugs for inhaled VIP therapy are commercially available under the trade name Aviptadil.
Colchicine is a substrate of the CYP3A4 metabolizing enzyme and the P-glycoprotein (P-gp) efflux transporter. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P- glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine). 

Patients with renal or hepatic impairment should not be given GLOPERBA with drugs that inhibit both CYP3A4 and P-glycoprotein [see Contraindications (4)]. Combining these dual inhibitors with GLOPERBA in patients with renal and hepatic impairment has resulted in life-threatening or fatal colchicine toxicity.

Physicians should ensure that patients are suitable candidates for treatment with GLOPERBA and remain alert for signs and symptoms of toxic reactions associated with increased colchicine exposure due to drug interactions. Signs and symptoms of colchicine toxicity should be evaluated promptly and, if toxicity is suspected, consider lowering the dose, interruption or discontinuation of GLOPERBA.
Contact tracing during an event is provided. Community interaction information for one or more clusters is determined. The community interaction information for a cluster correlates times and physical locations of one or more individuals within an area corresponding to the cluster. It is determined that a first individual has traveled from a first area corresponding to a first cluster to a second area corresponding to a second cluster. The determination is based, at least in part, on correlated times and physical locations of the first individual. One or more at-risk individuals is identified based, at least in part, on the community interaction information of the second cluster.
The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
The participants in the Neurocognitive training-only arm (nBCI) will undergo 48 cognitive training sessions over 24 weeks on the NeeuroCycle BCI Cognitive training system. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. The nBCI training protocol will deliver cognitive training modules that consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. Participants will navigate the virtual space of the cognitive training program by using arrow keys on the tablet.